Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Atherosclerosis. 2020 Nov 15;315:62–67. doi: 10.1016/j.atherosclerosis.2020.11.010

Table 1.

Participant characteristics

Total WSHS-1 sample (N=1504) Primary analysis sample (N=726) Primary analysis sample at final visit (N=726)
Mean (standard deviation) or N (%) Mean (standard deviation) or N (%) Mean (standard deviation) or N (%)
Age, years 44.7 (11.1) 46.1 (10.3) 53.6 (10.3)
Female sex, N (%) 876 (58.2%) 422 (58.1%) 422 (58.1%)
Race
 White, N (%) 1258 (83.9%) 608 (83.8%) 607 (83.6%)
 African-American, N (%) 204 (13.6%) 100 (13.8%) 105 (14.5%)
 Other, N (%) 42 (2.7%) 18 (2.4%) 14 (1.9%)
Study site
 Madison, N (%) 883 (58.7%) 430 (58.6%) 430 (58.6%)
 Milwaukee, N (%) 621 (41.3%) 304 (41.4%) 304 (41.4%)
Cigarettes/day 21.4 (8.9) 20.9 (8.7) 9.3 (10.0)
Smoking heaviness, pack-years 29.4 (20.4) 29.7 (19.2) 15.9 (19.2)
Weight, kg 83.7 (20.5) 84.0 (20.0) 87.6 (22.0)
Body-mass index, kg/m2 29.0 (6.5) 29.1 (6.3) 30.3 (6.8)
Systolic blood pressure, mmHg 119.4 (14.4) 119.3 (14.0) 127.0 (16.3)
 Antihypertensive medication, N (%) 73 (4.9%) 43 (6.0%) 242 (34.7%)
Total cholesterol, mg/dL 184.1 (35.5) 185.7 (34.9) 200.9 (40.9)
High-density lipoprotein cholesterol, mg/dL 42.0 (13.6) 42.6 (14.0) 52.5 (17.3)
*Triglycerides, mg/dL 120.9 (1.7) 123.4 (1.7) 128.1 (1.7)
Low-density lipoprotein cholesterol, mg/dL 119.0 (30.6) 119.4 (29.7) 118.4 (35.8)
 Lipid-lowering medication, N (%) 60 (4.0%) 36 (5.0%) 170 (24.4%)
Diagnosis of diabetes mellitus, N (%) 91 (6.1%) 40 (5.6%) 94 (13.8%)
 Hemoglobin A1C, % 5.57 (0.6) 5.59 (0.6) 5.9 (0.8)
 Antiglycemic medication, N (%) 35 (2.3%) 17 (2.3%) 58 (8.3%)
Carotid intima-media thickness, mm 0.67 (0.15) 0.64 (0.16) 0.73 (0.18)
Carotid plaque presence, N (%) 805 (55.1%) 399 (55.0%) 516 (71.1%)
Carotid plaque score, plaques 1.6 (2.1) 1.6 (2.0) 2.6 (2.6)
*

Geometric mean (standard deviation, log10 triglycerides)

HHS Vulnerability Disclosure